Brian Aguirre
YOU?
Author Swipe
View article: Polyunsaturated fatty acid balance modulates microglial state in a murine model of oxygen-induced neovascularization
Polyunsaturated fatty acid balance modulates microglial state in a murine model of oxygen-induced neovascularization Open
View article: GrB-Fc-KS49, an anti-EMP2 granzyme B fusion protein therapeutic alters immune cell infiltration and suppresses breast cancer growth
GrB-Fc-KS49, an anti-EMP2 granzyme B fusion protein therapeutic alters immune cell infiltration and suppresses breast cancer growth Open
Background Granzyme B (GrB) is a key effector molecule, delivered by cytotoxic T lymphocytes and natural killer cells during immune surveillance to induce cell death. Fusion proteins and immunoconjugates represent an innovative therapeutic…
View article: Epithelial Membrane Protein 2 (EMP2) Blockade Attenuates Pathological Neovascularization in Murine Oxygen-Induced Retinopathy
Epithelial Membrane Protein 2 (EMP2) Blockade Attenuates Pathological Neovascularization in Murine Oxygen-Induced Retinopathy Open
Our results suggest that EMP2 blockade could be a local and specific treatment modality for retinal neovascularization in oxygen-induced retinopathies, without systemic adverse effects.
View article: Figure S4 from <sup>89</sup>Zr-ImmunoPET for the Specific Detection of EMP2-Positive Tumors
Figure S4 from <sup>89</sup>Zr-ImmunoPET for the Specific Detection of EMP2-Positive Tumors Open
S4. DFO-conjugated anti-EMP2 mAb characteristics. A. Analysis of the various anti-EMP2−DFO conjugates using polyacrylamide gel electrophoresis (PAGE) showing changes in the migration of the intact antibody. B. Analysis of the various anti-…
View article: Figure S3 from <sup>89</sup>Zr-ImmunoPET for the Specific Detection of EMP2-Positive Tumors
Figure S3 from <sup>89</sup>Zr-ImmunoPET for the Specific Detection of EMP2-Positive Tumors Open
S3. EMP2 expression in cancer cell lines. A. Based on public repositories, upregulation of EMP2 occurs in breast, brain, and ovarian cancers, while downregulation is predicted in hematopoietic cancers. B, C. Flow cytometry studies using a …
View article: Figure S4 from <sup>89</sup>Zr-ImmunoPET for the Specific Detection of EMP2-Positive Tumors
Figure S4 from <sup>89</sup>Zr-ImmunoPET for the Specific Detection of EMP2-Positive Tumors Open
S4. DFO-conjugated anti-EMP2 mAb characteristics. A. Analysis of the various anti-EMP2−DFO conjugates using polyacrylamide gel electrophoresis (PAGE) showing changes in the migration of the intact antibody. B. Analysis of the various anti-…
View article: Figure S1 from <sup>89</sup>Zr-ImmunoPET for the Specific Detection of EMP2-Positive Tumors
Figure S1 from <sup>89</sup>Zr-ImmunoPET for the Specific Detection of EMP2-Positive Tumors Open
S1. Summary of human EMP2 expression. A. HPA-RNAseq data depicting EMP2 mRNA expression in normal tissues. The image is reproduced from (https:www.ncbi.nlm.nih.gov/gene/2013). B. Immunohistochemical staining of representative human tissues…
View article: Data from <sup>89</sup>Zr-ImmunoPET for the Specific Detection of EMP2-Positive Tumors
Data from <sup>89</sup>Zr-ImmunoPET for the Specific Detection of EMP2-Positive Tumors Open
Epithelial membrane protein-2 (EMP2) is upregulated in a number of tumors and therefore remains a promising target for mAb-based therapy. In the current study, image-guided therapy for an anti-EMP2 mAb was evaluated by PET in both syngenei…
View article: Supplementary Data from <sup>89</sup>Zr-ImmunoPET for the Specific Detection of EMP2-Positive Tumors
Supplementary Data from <sup>89</sup>Zr-ImmunoPET for the Specific Detection of EMP2-Positive Tumors Open
Supplemental Figure Legends
View article: Figure S1 from <sup>89</sup>Zr-ImmunoPET for the Specific Detection of EMP2-Positive Tumors
Figure S1 from <sup>89</sup>Zr-ImmunoPET for the Specific Detection of EMP2-Positive Tumors Open
S1. Summary of human EMP2 expression. A. HPA-RNAseq data depicting EMP2 mRNA expression in normal tissues. The image is reproduced from (https:www.ncbi.nlm.nih.gov/gene/2013). B. Immunohistochemical staining of representative human tissues…
View article: Supplemental Tables from <sup>89</sup>Zr-ImmunoPET for the Specific Detection of EMP2-Positive Tumors
Supplemental Tables from <sup>89</sup>Zr-ImmunoPET for the Specific Detection of EMP2-Positive Tumors Open
Supplemental Tables
View article: Data from <sup>89</sup>Zr-ImmunoPET for the Specific Detection of EMP2-Positive Tumors
Data from <sup>89</sup>Zr-ImmunoPET for the Specific Detection of EMP2-Positive Tumors Open
Epithelial membrane protein-2 (EMP2) is upregulated in a number of tumors and therefore remains a promising target for mAb-based therapy. In the current study, image-guided therapy for an anti-EMP2 mAb was evaluated by PET in both syngenei…
View article: Figure S3 from <sup>89</sup>Zr-ImmunoPET for the Specific Detection of EMP2-Positive Tumors
Figure S3 from <sup>89</sup>Zr-ImmunoPET for the Specific Detection of EMP2-Positive Tumors Open
S3. EMP2 expression in cancer cell lines. A. Based on public repositories, upregulation of EMP2 occurs in breast, brain, and ovarian cancers, while downregulation is predicted in hematopoietic cancers. B, C. Flow cytometry studies using a …
View article: Figure S5 from <sup>89</sup>Zr-ImmunoPET for the Specific Detection of EMP2-Positive Tumors
Figure S5 from <sup>89</sup>Zr-ImmunoPET for the Specific Detection of EMP2-Positive Tumors Open
S5. Binding characteristics. Analysis of the various anti-EMP2−DFO conjugates using flow cytometry binding on U87MG/EMP2FLuc. N=3, with the EC50 determined using nonlinear regression. B. 10:1 DFO:mAb ratio retains specific binding to EMP2 …
View article: Supplemental Tables from <sup>89</sup>Zr-ImmunoPET for the Specific Detection of EMP2-Positive Tumors
Supplemental Tables from <sup>89</sup>Zr-ImmunoPET for the Specific Detection of EMP2-Positive Tumors Open
Supplemental Tables
View article: Figure S5 from <sup>89</sup>Zr-ImmunoPET for the Specific Detection of EMP2-Positive Tumors
Figure S5 from <sup>89</sup>Zr-ImmunoPET for the Specific Detection of EMP2-Positive Tumors Open
S5. Binding characteristics. Analysis of the various anti-EMP2−DFO conjugates using flow cytometry binding on U87MG/EMP2FLuc. N=3, with the EC50 determined using nonlinear regression. B. 10:1 DFO:mAb ratio retains specific binding to EMP2 …
View article: Figure S7 from <sup>89</sup>Zr-ImmunoPET for the Specific Detection of EMP2-Positive Tumors
Figure S7 from <sup>89</sup>Zr-ImmunoPET for the Specific Detection of EMP2-Positive Tumors Open
S7. ImmunoPET imaging with 89Zr-DFO- anti-EMP2 mAb of U87MG/EMP2Fluc or sham injected nude mouse in an intracranial model. All mice received the same surgical procedures, but they were injected with either U87MG/EMP2Fluc cells or saline (s…
View article: Supplementary Data from <sup>89</sup>Zr-ImmunoPET for the Specific Detection of EMP2-Positive Tumors
Supplementary Data from <sup>89</sup>Zr-ImmunoPET for the Specific Detection of EMP2-Positive Tumors Open
Supplemental Figure Legends
View article: Figure S2 from <sup>89</sup>Zr-ImmunoPET for the Specific Detection of EMP2-Positive Tumors
Figure S2 from <sup>89</sup>Zr-ImmunoPET for the Specific Detection of EMP2-Positive Tumors Open
S2. EMP2 expression in the mouse. Expression of EMP2 was determined by immunohistochemical staining in C57B/6 WT or EMP2 knockout mice with representative images shown from select tissue. Magnification: 400X.
View article: Figure S7 from <sup>89</sup>Zr-ImmunoPET for the Specific Detection of EMP2-Positive Tumors
Figure S7 from <sup>89</sup>Zr-ImmunoPET for the Specific Detection of EMP2-Positive Tumors Open
S7. ImmunoPET imaging with 89Zr-DFO- anti-EMP2 mAb of U87MG/EMP2Fluc or sham injected nude mouse in an intracranial model. All mice received the same surgical procedures, but they were injected with either U87MG/EMP2Fluc cells or saline (s…
View article: Figure S2 from <sup>89</sup>Zr-ImmunoPET for the Specific Detection of EMP2-Positive Tumors
Figure S2 from <sup>89</sup>Zr-ImmunoPET for the Specific Detection of EMP2-Positive Tumors Open
S2. EMP2 expression in the mouse. Expression of EMP2 was determined by immunohistochemical staining in C57B/6 WT or EMP2 knockout mice with representative images shown from select tissue. Magnification: 400X.
View article: Figure S6 from <sup>89</sup>Zr-ImmunoPET for the Specific Detection of EMP2-Positive Tumors
Figure S6 from <sup>89</sup>Zr-ImmunoPET for the Specific Detection of EMP2-Positive Tumors Open
S6. Pharmacokinetics and in vivo tumor expression. A. Tumor growth of syngeneic 4T1FLuc, CT26, and Panc02 tumors over the imaging period. B. Correlation of the average EMP2 histological score and mean %ID/cc in 4T1FLuc, CT26 and Panc02 tum…
View article: Figure S6 from <sup>89</sup>Zr-ImmunoPET for the Specific Detection of EMP2-Positive Tumors
Figure S6 from <sup>89</sup>Zr-ImmunoPET for the Specific Detection of EMP2-Positive Tumors Open
S6. Pharmacokinetics and in vivo tumor expression. A. Tumor growth of syngeneic 4T1FLuc, CT26, and Panc02 tumors over the imaging period. B. Correlation of the average EMP2 histological score and mean %ID/cc in 4T1FLuc, CT26 and Panc02 tum…
View article: EMP2 Serves as a Functional Biomarker for Chemotherapy-Resistant Triple-Negative Breast Cancer
EMP2 Serves as a Functional Biomarker for Chemotherapy-Resistant Triple-Negative Breast Cancer Open
Breast cancer (BC) remains among the most commonly diagnosed cancers in women worldwide. Triple-negative BC (TNBC) is a subset of BC characterized by aggressive behavior, a high risk of distant recurrence, and poor overall survival rates. …
View article: Resveratrol Supplementation in Conventional Slow or Ultra-Rapid Freezing Medium Enhances Post-Thaw Quality and Fertility of Bull Spermatozoa
Resveratrol Supplementation in Conventional Slow or Ultra-Rapid Freezing Medium Enhances Post-Thaw Quality and Fertility of Bull Spermatozoa Open
View article: ANGI-11. MOLECULAR MECHANISM OF TARGETING EPITHELIAL MEMBRANE PROTEIN-2 IN MALIGNANT MENINGIOMAS
ANGI-11. MOLECULAR MECHANISM OF TARGETING EPITHELIAL MEMBRANE PROTEIN-2 IN MALIGNANT MENINGIOMAS Open
BACKGROUND Meningiomas comprise approximately one-third of all primary central nervous system neoplasms. While many meningiomas remain benign, as many as 35% of meningiomas are graded as atypical or anaplastic/malignant with a 5-y survival…
View article: Exploring the Past, Present, and Future of Anti-Angiogenic Therapy in Glioblastoma
Exploring the Past, Present, and Future of Anti-Angiogenic Therapy in Glioblastoma Open
Glioblastoma, a WHO grade IV astrocytoma, constitutes approximately half of malignant tumors of the central nervous system. Despite technological advancements and aggressive multimodal treatment, prognosis remains dismal. The highly vascul…
View article: Epithelial membrane protein 2 (EMP2): A systematic review of its implications in pathogenesis
Epithelial membrane protein 2 (EMP2): A systematic review of its implications in pathogenesis Open
Overall, the evidence suggests the mechanisms of action of EMP2 are context dependent. Promising results have been produced by utilizing EMP2 as a biomarker and therapeutic target. More studies are warranted to better understand the mechan…
View article: Epithelial membrane protein 2 (EMP2) regulates hypoxia-induced angiogenesis in the adult retinal pigment epithelial cell lines
Epithelial membrane protein 2 (EMP2) regulates hypoxia-induced angiogenesis in the adult retinal pigment epithelial cell lines Open
View article: ANGI-10. IMPLICATIONS OF EPITHELIAL MEMBRANE PROTEIN-2 (EMP2) IN THE PATHOGENESIS OF MENINGIOMAS
ANGI-10. IMPLICATIONS OF EPITHELIAL MEMBRANE PROTEIN-2 (EMP2) IN THE PATHOGENESIS OF MENINGIOMAS Open
INTRODUCTION VEGF-A is an important mediator of angiogenesis in meningiomas. However, targeting this protein with bevacizumab has offered only a modest improvement in survival, suggesting that there are other compensatory mechanisms involv…